| Features: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Mild Hyperthermia (Approximately 39°C to 41°C Pathways and Effects: -Heat Shock Protein (HSP) Induction: Mild heat stress triggers the production of HSPs (e.g., HSP70, HSP90) that help cells cope with stress, which can sometimes provide a transient protective effect. However, these proteins can also act as immunomodulators. -Modulation of the Immune System: Mild hyperthermia can enhance dendritic cell activation and improve antigen presentation, leading to the stimulation of anti-tumor immune responses. -Vasodilation: Increased blood flow and improved oxygenation can sensitize tumors to radiation therapy and certain chemotherapeutics. Moderate Hyperthermia (Approximately 41°C to 43°C) Pathways and Effects: -Enhanced Cytotoxicity: At temperatures in this range, tumor cells become more vulnerable to radiation and some chemotherapeutic agents. This is partly due to the inhibition of DNA repair pathways. -Increased Permeability: Moderate heat can increase the permeability of cellular membranes, aiding in drug delivery and the uptake of chemotherapeutic agents. -Induction of Apoptosis: Elevated temperatures can trigger apoptotic signaling pathways in cancer cells, sometimes in conjunction with other therapies. High Hyperthermia / Thermal Ablation (Approximately 43°C to 50°C and above) Pathways and Effects: -Direct Cytotoxicity: High temperatures can lead to protein denaturation, membrane disruption, and direct cell death. -Coagulative Necrosis: Sustained high temperatures cause irreversible cell injury leading to necrosis of tumor tissues. -Vascular Damage: Hyperthermia in this range can damage tumor vasculature, reducing blood supply and indirectly causing tumor cell death. -Enhanced Immune Response: Although high temperatures can cause immediate cell death, the release of tumor antigens and damage-associated molecular patterns (DAMPs) can stimulate an anti-tumor immune response Hyperthermia — a physical anticancer treatment modality in which tumor tissue is deliberately heated, usually to approximately 39–43°C for tens of minutes, using electromagnetic energy, ultrasound, infrared heating, heated perfusate, or related techniques. It is formally classified as a thermal therapy rather than a drug and is most commonly abbreviated HT; the Nestronics database uses HPT. Local, superficial, interstitial, and regional hyperthermia are distinct from thermal ablation, where substantially greater thermal doses are intended to directly destroy tissue. Therapeutic hyperthermia is primarily used as an adjunct to radiotherapy or chemotherapy rather than as a stand-alone systemic cancer treatment. Its biological activity depends strongly on temperature, duration, spatial temperature distribution, tumor perfusion, and timing relative to other therapy. Primary mechanisms (ranked):
Bioavailability / PK relevance: Not applicable in the conventional pharmacokinetic sense because hyperthermia is a locally delivered physical modality rather than a circulating drug. The analogous exposure variable is thermal dose, commonly characterized by achieved temperature, treatment duration, spatial coverage, and metrics such as cumulative equivalent minutes at 43°C. Clinical effectiveness depends on adequate and reasonably homogeneous heating of the target while limiting normal-tissue hot spots. Tumor depth, perfusion, tissue composition, applicator geometry, coupling, thermometry, and treatment planning are therefore major delivery constraints. In-vitro vs systemic exposure relevance: Hyperthermia is not concentration-driven. In-vitro temperature exposures can be tightly controlled and spatially uniform, whereas clinical tumors commonly exhibit substantial temperature heterogeneity. Mechanistic findings obtained at 41–43°C are clinically relevant when comparable intratumoral thermal doses are actually achieved; experiments at higher temperatures or prolonged exposures increasingly model thermal ablation rather than conventional oncologic hyperthermia. Clinical evidence status: RCT-supported adjunct treatment in selected cancers, particularly in combination with radiotherapy, re-irradiation, or chemotherapy. Randomized studies demonstrate improved local response or progression-related outcomes in settings including superficial or recurrent breast tumors, locally advanced pelvic tumors, and high-risk soft-tissue sarcoma. Survival benefit is disease- and regimen-dependent and has not been demonstrated uniformly. Hyperthermia remains specialized and is not widely available. FDA-regulated RF/microwave hyperthermia systems have been cleared or approved for defined oncologic indications. Major practical limitations are achieving adequate target thermal dose, avoiding normal-tissue hot spots, specialized equipment and expertise, and integration with radiotherapy or chemotherapy. Local adverse effects include discomfort, pain, burns and blistering; regional perfusion and whole-body techniques have additional systemic risks. Hyperthermia Cancer-Relevant Mechanisms
P: 0–30 min R: 30 min–3 hr G: >3 hr ul> |
| Source: NA |
| Type: NA |
| NA |
| 7599- | HPT, | Rad, | Recent development on hyperthermia: An effective cotreatment improving radiotherapy outcome |
| - | Review, | Var, | NA |
| 7618- | HPT, | ESHO 2-85. Hyperthermia as an adjuvant to radiation therapy in the treatment of advanced neck nodes: A randomized multicenter study by the European Society for Hyperthermic Oncology |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:98 Target#:0 State#:% Dir#:2
wNotes=0 sortOrder:rid,rpid